| --- | --- | --- | --- | |------------------------------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | Developing a Differentiated | | | | | FGF21 for Non-Alcoholic Steatohepatitis (NASH) and Severe Hypertriglyceridemia (SHTG) | | | | | Nasdaq: ETNB | | | | | August 2020 | | | | Disclaimer 1 Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities law ...